Literature DB >> 725551

HLA antigens in females with ankylosing spondylitis and other forms of seronegative rheumatic diseases.

J Säfwenberg, B Domeij-Nyberg, M Kjällman.   

Abstract

A total of 222 female patients with seronegative rheumatic diseases were investigated by sacroiliac joint X-ray and HLA-A, B and Ctyped. The frequency of the B27 antigen was significantly increased in the following groups: definite pelvospondylitis (26 patients and relative risk (RR) = 99), possible pelvospondylitis (20 patients, RR=4.5), definite sacroiliitis (14 patients, RR-20.1) and uroarthritis (8 patients). When 24 B27 negative patients from these B27 associated diseases were analysed, significantly increased frequencies of the BW22 (RR=16.7) and CW1 (RR=14.4) antigens were found. There were no significantly deviating HLA frequencies in the following diagnostic groups: clinical sacroiliitis (20 patients), polyarthritis with clinically silent sacroiliitis (12 patients), polyarthritis without sacroiliitis (47 patients), arthralgia preceded by beta-streptococcal infection (17 patients), other arthralgia (33 patients), osteo-arthritis (13 patients) and other arthritis (12 patients).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 725551     DOI: 10.3109/03009747809095650

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  3 in total

1.  Increased incidence of faecal Klebsiella pneumoniae in patients with HLA B7 CREG antigen and men with rheumatoid arthritis.

Authors:  R Ebringer; D Colthorpe; A Young; M Corbett
Journal:  Br Med J       Date:  1980-08-30

2.  HLA-B alleles and complotypes in Mexican patients with seronegative spondyloarthropathies.

Authors:  G Vargas-Alarcón; A Garcia; S Bahena; H Melin-Aldana; F Andrade; G Ibañez-de-Kasep; J Alcocer-Varela; D Alarcón-Segovia; J Granados
Journal:  Ann Rheum Dis       Date:  1994-11       Impact factor: 19.103

Review 3.  HLA-Cw1 and Psoriasis.

Authors:  Yi-Wei Huang; Tsen-Fang Tsai
Journal:  Am J Clin Dermatol       Date:  2021-01-18       Impact factor: 7.403

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.